共 50 条
- [1] ORPHAN DRUGS: HEALTH TECHNOLOGY ASSESSMENT AND PRICING IN EUROPE[J]. VALUE IN HEALTH, 2018, 21 : S24 - S24Jaroslawski, S.Toumi, M.Korchagina, D.Jadot, G.
- [2] HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR ORPHAN DRUGS IN COST-EFFECTIVENESS (CE) MARKETS: CURRENT DEVELOPMENT AND FUTURE TRENDS[J]. VALUE IN HEALTH, 2016, 19 (07) : A601 - A601Zhang, A.Weisse, S.Chen, X.
- [3] A COMPARATIVE ANALYSIS OF PRIORITIES AND METHODS OF HEALTH TECHNOLOGY ASSESSMENT (HTA) OF DRUGS IN SELECTED COUNTRIES[J]. VALUE IN HEALTH, 2022, 25 (01) : S190 - S190Vutova, Y.Djambazov, S.Slavchev, G.Dacheva, A.
- [5] PROVISIONS AND SPECIAL CONSIDERATIONS FOR RARE DISEASES / ORPHAN DRUGS BY HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES: SYSTEMATIC EVALUATION IN 25 COUNTRIES[J]. VALUE IN HEALTH, 2016, 19 (07) : A602 - A602Mwamburi, M.Nanavaty, M.Gala, S.Nyandege, A.Ramesh, V
- [7] Thematic analysis in integrated health technology assessment (HTA)[J]. QUALITY OF LIFE RESEARCH, 2020, 29 (SUPPL 1) : S178 - S178English, BethanyMumford, AndrewMunetsi, Lorraine
- [8] HTA OUTCOMES FOR ORPHAN DRUGS IN ONCOLOGY: COMPARISON OF FRANCE, GERMANY AND ENGLAND[J]. VALUE IN HEALTH, 2018, 21 : S111 - S111Jaroslawski, S.Toumi, M.Korchagina, D.Auquier, P.Dussart, C.
- [9] HTA STUDIES ON ORPHAN DRUGS BY REBRATSXMEMBERS[J]. VALUE IN HEALTH, 2014, 17 (07) : A540 - A540Souza, K. M.Goncalves, L.
- [10] ORPHAN DRUGS ASSESSMENT IN GERMANY: A COMPARISON WITH OTHER INTERNATIONAL HTA AGENCIES[J]. VALUE IN HEALTH, 2015, 18 (07) : A550 - A551Mycka, J.Dellamano, R.Lobb, W.Dellamano, L.Dalal, N.